Stroke & Neurocritical Care Trials

As part of an academic medical center, the Division of Stroke & Neurocritical Care at Northwestern University Feinberg School of Medicine aims to improve human health through scientific research. Clinical trials test or study drugs, surgical procedures, medical devices or interventions with human subjects. They look to determine their safety and effectiveness in relation to treating specific diseases. Clinical trials are part of clinical research and are at the heart of all medical advances.

The following searchable list includes all the stroke and neurocritical care clinical trials currently looking for participants.

Search Studies

Trials
cIRB: AtRial Cardiopathy and Antithrombotic Drugs In prevention After Crypotgenic Stroke ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of u… ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage. Eligibility CriteriaInclusion Criteria: Age ≥ 45 years. Clinical diagnosis of ischemic stroke + brain imaging to rule out hemorrhagic stroke. Modified Rankin Scale (MRS) score ≤ 4. Ability to be randomized within 3 to 120 days after stroke onset. ESUS (embolic stroke of underdetermined source). Exclusion Criteria: History of atrial fibrillation Clear indication for treatment-dose anticoagulant therapy, such as venous thromboembolism or a mechanical heart valve. Need for antiplatelet agent other than aspirin, such as clopidogrel after implantation of a coronary artery stent. History of spontaneous intracranial hemorrhage. Chronic kidney disease with serum creatinine ≥2.5 mg/dL. Principal Investigator Caprio, Fan Zhang Location(s) Map it 201 E. Huron St. Chicago, IL Map it Lavin Pavillion 259 E. Erie St., Suite 19-100 Chicago, IL ClinicalTrials.gov IdentifierNCT03192215IRB number STU00206251 More Info Keywords stroke apixaban cryptogenic aspirin unknown cause esus Email Garcia-Canga, Blas Ignacio Phone +1 312 503 0492 Copy Study URL to Clipboard Copy
AtRial Cardiopathy and Antithrombotic Drugs In prevention After Crypotgenic Stroke- Cognition and Silent Infarcts ARCADIA-CSI an ancillary study to the ARCADIA trial in which we will assess cognitive function and silent infarcts in a subset of the ARCADIA population. The purpose of ARCADIA-CSI i… ARCADIA-CSI an ancillary study to the ARCADIA trial in which we will assess cognitive function and silent infarcts in a subset of the ARCADIA population. The purpose of ARCADIA-CSI is to determine the effect of apixaban vs aspirin on these two additional outcomes in patients with stroke of unknown cause and atrial cardiopathy. Eligibility CriteriaPatients randomized in the ARCADIA trial and on study drug will be eligible for ARCADIA-CSI if they can undergo cognitive testing (english speaking) and have no MRI contraindications. Principal Investigator Caprio, Fan Zhang Location(s) Map it Lavin Pavillion 259 E. Erie St., Suite 19-100 Chicago, IL Map it 201 E. Huron St. Chicago, IL ClinicalTrials.gov IdentifierNCT03192215IRB number STU00211262 More Info Keywords apixaban stroke crytogenic esus aspirin unknown case Email Garcia-Canga, Blas Ignacio Phone +1 312 503 0492 Copy Study URL to Clipboard Copy
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2) (Protocol #: B01-04) A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem®, in adults who have suffered an acute ischemic stroke in the pre… A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem®, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours. Eligibility Criteria Primary Inclusion Criteria: Male or female subjects ≥18 years of age Clinical diagnosis of ischemic stroke involving cerebral cortex Onset of stroke symptoms must have occurred 18 to 36 hours prior to the planned start of administration of the investigational product Occurrence of a moderate to moderately severe stroke with a persistent neurologic deficit documented by a NIHSS score of 8 to 20 (inclusive) that does not change by ≥4 points during the initial screening period A mRS score of 0 or 1 prior to the onset of symptoms of the current stroke Primary Exclusion Criteria: Presence of a lacunar or a brainstem infarct Comatose state Brain hemorrhage Major neurological event such as stroke or clinically significant head trauma within 6 months of enrollment into the study Principal Investigator Batra, Ayush Location(s) Map it Lavin Pavillion 259 E. Erie St., Suite 19-100 Chicago, IL Map it 201 E. Huron St. Chicago, IL ClinicalTrials.gov IdentifierNCT03545607IRB number STU00209969 More Info Keywords stroke stem cell multistem stroke treatment stroke recovery ischemic stroke Email Garcia-Canga, Blas Ignacio Phone +1 312 503 0492 Copy Study URL to Clipboard Copy